Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? BioPharma DiveWhile many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.OncologyRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioPharma Dive While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s salanersen gains FDA breakthrough therapy designation for SMANext: Stakeholders want Makary’s voucher program paused, call for FDA independence Related Stories Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026 Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026
